Oral Teriflunomide study shows lasting efficacy and safety
Oral Teriflunomide study shows lasting efficacy and safety
The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of follow-up in clinical trial patients with the relapsing form of multiple sclerosis, and no late safety problems have been noticed, researchers said here.
The findings came from open-label extensions of phase II and III studies with teriflunomide, which is now under FDA review as a treatment for relapsing-remitting MS. The results were presented in a series of posters at the joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2284 Views
-
Last post by NHE
-
- 0 Replies
- 1407 Views
-
Last post by frodo
-
- 0 Replies
- 11285 Views
-
Last post by NHE
-
- 0 Replies
- 1043 Views
-
Last post by frodo
-
- 0 Replies
- 1807 Views
-
Last post by Tif
-
- 1 Replies
- 1228 Views
-
Last post by Petr75
-
- 0 Replies
- 247 Views
-
Last post by NHE
-
- 0 Replies
- 2312 Views
-
Last post by DIM
-
- 0 Replies
- 2550 Views
-
Last post by DIM